BI 836909

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 836909, covering 2021-07-22 to 2021-07-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients [Phase 1]